Discloses the use of follicle stimulating hormone (FSH) for the manufacture of a product for the treatment of infertility in a patient； wherein if the patient has serum AMH level of less than15 pmol/L, the product comprises a daily dose of, or daily dose equivalent to, 11 to 13 &mu；g recombinant FSH, the recombinant FSH includes &alpha；2, 3- and &alpha；2, 6- sialylation where 1% to 99% of the total sialylation is &alpha；2, 6- sialyation, and 1% to 99% of the total sialylation is &alpha； 2,3- sialyation； or wherein if the patient has serum AMH level of greater than 15 pmol/L, the product is formulated to be administered at a daily dose of, or daily dose equivalent to, 0.09 to 0.19 &mu；g recombinant FSH per kg bodyweight of the patient, the recombinant FSH including &alpha；2, 3- and &alpha；2, 6- sialylation wherein 1% to 99% of the total sialylation is &alpha；2, 6- sialyation, and 1% to 99% of the total sialylation is &alpha； 2,3- sialyation.
